{"title":"Lean Six Sigma as a Management Tool Helps Standardize Antimicrobial Use in Hospital Settings.","authors":"Qian Wang, Xinru Han, Xiang Zhang, Lubo Guo","doi":"10.2147/DDDT.S510926","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to standardize antimicrobial use in a hospital setting by implementing the Lean Six Sigma (LSS)-DMAIC model (Define, Measure, Analyze, Improve, Control), addressing the irrational use of antibacterial drugs.</p><p><strong>Methods: </strong>A retrospective analysis was conducted using data from a single hospital's information system in Shandong, China, covering antibacterial drug usage from January 2020 to December 2021. The LSS-DMAIC framework was applied, which involved defining problems, measuring key indicators, analyzing causes of irrational use, implementing improvement measures, and controlling outcomes. The project team comprised clinical pharmacists and healthcare professionals who evaluated antibiotic use and compliance with guidelines.</p><p><strong>Results: </strong>In the whole hospital, the management through LSS-DMAIC led to a significant reduction in the non-standard utilization rate of antibacterial drugs from 32.5% to 11.3% (P < 0.0001), achieving the set target. The intensity of antibacterial drug use decreased to 38.82 Defined Daily Doses (DDDs), meeting national standards. Additionally, the utilization rate of antibacterial drugs has dropped from 43.61% to 40.16% (P < 0.0001), and the average cost of antibacterial drugs per inpatient significantly dropped from 1909.59 RMB (known as Renminbi, which is the legal currency of China) to 1675.20 RMB (P < 0.0001), resulting in substantial annual savings.</p><p><strong>Conclusion: </strong>The application of the LSS-DMAIC model effectively improved the rational use of antibacterial drugs in the hospital, demonstrating its potential as a valuable management tool in healthcare settings. Continued efforts are necessary to sustain these improvements and further enhance clinician adherence to antimicrobial stewardship practices.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"3539-3554"},"PeriodicalIF":4.7000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050037/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S510926","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study aimed to standardize antimicrobial use in a hospital setting by implementing the Lean Six Sigma (LSS)-DMAIC model (Define, Measure, Analyze, Improve, Control), addressing the irrational use of antibacterial drugs.
Methods: A retrospective analysis was conducted using data from a single hospital's information system in Shandong, China, covering antibacterial drug usage from January 2020 to December 2021. The LSS-DMAIC framework was applied, which involved defining problems, measuring key indicators, analyzing causes of irrational use, implementing improvement measures, and controlling outcomes. The project team comprised clinical pharmacists and healthcare professionals who evaluated antibiotic use and compliance with guidelines.
Results: In the whole hospital, the management through LSS-DMAIC led to a significant reduction in the non-standard utilization rate of antibacterial drugs from 32.5% to 11.3% (P < 0.0001), achieving the set target. The intensity of antibacterial drug use decreased to 38.82 Defined Daily Doses (DDDs), meeting national standards. Additionally, the utilization rate of antibacterial drugs has dropped from 43.61% to 40.16% (P < 0.0001), and the average cost of antibacterial drugs per inpatient significantly dropped from 1909.59 RMB (known as Renminbi, which is the legal currency of China) to 1675.20 RMB (P < 0.0001), resulting in substantial annual savings.
Conclusion: The application of the LSS-DMAIC model effectively improved the rational use of antibacterial drugs in the hospital, demonstrating its potential as a valuable management tool in healthcare settings. Continued efforts are necessary to sustain these improvements and further enhance clinician adherence to antimicrobial stewardship practices.
期刊介绍:
Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.
The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.
Specific topics covered by the journal include:
Drug target identification and validation
Phenotypic screening and target deconvolution
Biochemical analyses of drug targets and their pathways
New methods or relevant applications in molecular/drug design and computer-aided drug discovery*
Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)
Structural or molecular biological studies elucidating molecular recognition processes
Fragment-based drug discovery
Pharmaceutical/red biotechnology
Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**
Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development
Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)
Preclinical development studies
Translational animal models
Mechanisms of action and signalling pathways
Toxicology
Gene therapy, cell therapy and immunotherapy
Personalized medicine and pharmacogenomics
Clinical drug evaluation
Patient safety and sustained use of medicines.